Hangzhou Adamerck Pharmlabs Inc. announced that its independently developed Class 1 innovative drug Aom0498 has received marketing approval from China’s National Medical Products Administration (NMPA), effective July 1, 2026. The new-generation specific neuromuscular blockade reversal agent represents China’s first domestically developed therapy in this critical perioperative category, completing a development journey supported by the National … Continue reading Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program